Advertisement

ADVERTISEMENT

DLBCL

Dr W
Videos
Dr Westin on Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and With Chemo for DLBCL
02/14/2022
Jason Westin, MD, discusses a phase 2 study on lenalidomide, tafasitamab, rituximab, and acalabrutinib alone or in combination with chemotherapy in patients with newly diagnosed DLBCL, presented at ASH 2021.
Jason Westin, MD, discusses a phase 2 study on lenalidomide, tafasitamab, rituximab, and acalabrutinib alone or in combination with chemotherapy in patients with newly diagnosed DLBCL, presented at ASH 2021.
Jason Westin, MD, discusses a...
02/14/2022
Oncology
Dr S
Videos
Dr Shah Highlights a First in-Human Study of YTB323 for Patients With R/R DLBCL
02/11/2022
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a...
02/11/2022
Oncology
Dr Ghosh
Videos
Dr Ghosh Overviews Glofitamab Plus R-CHOP for R/R NHL, Including FL, DLBCL
01/13/2022
Nilanjan Ghosh, MD, highlights preliminary results from a dose-escalation and safety run-in phase 1b study of glofitamab plus R-CHOP for patients with R/R NHL and previously untreated DLBCL, presented at ASH 2021.
Nilanjan Ghosh, MD, highlights preliminary results from a dose-escalation and safety run-in phase 1b study of glofitamab plus R-CHOP for patients with R/R NHL and previously untreated DLBCL, presented at ASH 2021.
Nilanjan Ghosh, MD, highlights...
01/13/2022
Oncology
News
Comparing R-MiniCHOP With or Without Azacitidine in Patients With Lymphomas, Including DLBCL
01/10/2022
A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...
A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...
A randomized study of R-miniCHOP...
01/10/2022
Oncology
News
Acalabrutinib Plus AZD9150 is Safe and Effective in Patients With R/R DLBCL
01/04/2022
Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.
Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.
Data of the combination of...
01/04/2022
Oncology
News
Phase 1b Trial Shows Safety of CD19-7x19 CAR-T Cells in Combination With Anti-PD-1 Antibody for R/R DLBCL
01/04/2022
Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.
Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.
Data of CD19-7x19 CAR-T cells...
01/04/2022
Oncology
News
Extranodal Presentation is Not a Prognostic Marker in Limited Stage DLBCL
12/22/2021
Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.
Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.
Data analyses from the 3...
12/22/2021
Oncology
Dr Burke
Videos
Dr Burke Highlights POLARIX Study on Pola-R-CHP vs R-CHOP for Patients With DLBCL
12/22/2021
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the phase 3 POLARIX study on pola-R-CHP versus R-CHOP for patients with previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
Dr Burke
Videos
Dr Burke Discusses Umbralisib and Ublituximab Plus Bendamustine for Patients With R/R DLBCL
12/22/2021
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the efficacy and safety of umbralisib, ublituximab, and bendamustine for patients with R/R DLBCL. These data were presented at the 2021 ASH Annual Meeting.
John Burke, MD, discusses the...
12/22/2021
Oncology
dr k
Videos
Dr Kannan Highlights Subasumstat Plus Rituximab for CD20+ R/R NHL, Including DLBCL
12/16/2021
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD, highlights subasumstat in combination with rituximab for CD20+ R/R NHL, including DLBCL, and more. These data were presented at the 2021 ASH Annual Meeting.
Karuppiah Kannan, PhD,...
12/16/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Cape Cod Symposium
September 5 ⁠–⁠ September 8
September 6 ⁠–⁠ September 8
EMS World Expo
September 9 ⁠–⁠ September 13
Psych Congress Regionals
September 12 ⁠–⁠ September 13
September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use